Tamura Yuichi, Hosokawa Kazuya, Horimoto Koshin, Ikeda Satoshi, Inami Takumi, Kubota Kayoko, Nakanishi Naohiko, Shirai Yuichiro, Tanabe Nobuhiro, Tsujino Ichizo, Matsubara Hiromi
Pulmonary Hypertension Center, International University of Health and Welfare Mita Hospital, Tokyo 108-8329, Japan.
Department of Cardiology, International University of Health and Welfare School of Medicine, Narita 286-8520, Japan.
Diagnostics (Basel). 2024 Nov 25;14(23):2656. doi: 10.3390/diagnostics14232656.
Quality indicators (QIs) are used to standardize care and improve outcomes in patients with pulmonary arterial hypertension (PAH). It is important that QIs are validated within specific healthcare contexts. Therefore, this study aimed to validate QIs for PAH management in Japan using a modified Delphi consensus method.
QI candidates were identified from published European QIs and clinical practice guidelines. An expert panel of 11 PAH specialists from diverse Japanese institutions anonymously rated the 36 initial QI candidates in two rounds using a nine-point appropriateness scale.
In the first round, 35 QIs received a median score of ≥7 points. A panel discussion was held between rounds to address the single low-scored QI, biomarker modifications, and invasive examinations, resulting in 36 modified QIs. In the second round, all modified QIs received median scores of ≥7 points and were judged to be valid as the final Japanese set of QIs.
The findings of this study validated a set of QIs for PAH management tailored to the Japanese healthcare context. These QIs can be used to standardize care, identify areas for improvement, and ultimately enhance outcomes for Japanese patients with PAH.
质量指标(QIs)用于规范肺动脉高压(PAH)患者的治疗并改善其预后。在特定的医疗环境中验证质量指标很重要。因此,本研究旨在使用改良的德尔菲共识法验证日本PAH管理的质量指标。
从已发表的欧洲质量指标和临床实践指南中确定质量指标候选项目。来自日本不同机构的11名PAH专家组成的专家小组,使用九点适宜性量表对36个初始质量指标候选项目进行两轮匿名评分。
在第一轮中,35个质量指标的中位数得分≥7分。两轮评分之间举行了小组讨论,以讨论得分较低的单个质量指标、生物标志物修改和侵入性检查,从而产生了36个修改后的质量指标。在第二轮中,所有修改后的质量指标中位数得分均≥7分,并被判定为有效的日本最终质量指标集。
本研究结果验证了一套针对日本医疗环境量身定制的PAH管理质量指标。这些质量指标可用于规范治疗、确定改进领域,并最终改善日本PAH患者的预后。